Eli Lilly, Merck, and Gilead Sciences are set to report their Q3 2026 earnings on October 29, with Eli Lilly facing lowered EPS estimates amid strong GLP-1 drug demand, Merck dealing with tough comparisons for its cancer drug Keytruda, and Gilead managing cash burn despite steady HIV sales. Eli Lilly’s international growth and new drug launches will be key to offset U.S. price declines, while Merck’s outlook hinges on Keytruda’s performance before losing exclusivity in 2028. Gilead’s focus remains on HIV product strength and upcoming drug launches, with investors watching its shrinking cash reserves. These reports will influence investor sentiment and sector expectations going forward.
Eli Lilly trades at USD 1,275.85 with a slight 0.47% decline on Pluang as of Oct 28, 2026 19:11 WIB, reflecting cautious investor sentiment ahead of its Q3 earnings. Merck shares are down 1.07% at USD 140.30, while Gilead Sciences is priced at USD 158.02, down 0.67%, showing mixed reactions among investors to the upcoming reports. Pluang order activity shows strong buy interest for Eli Lilly at 92%, moderate buy interest for Merck at 83%, and a majority sell sentiment for Gilead at 68%.
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
Eli Lilly announced that Patrik Jonsson, executive vice president and president of Lilly International, will retire at the end of 2026 after a 36-year career. Starting January 1, 2027, Ilya Yuffa will take on an expanded role as executive vice presid...
In 2026, an S&P 500 index excluding AI-related stocks briefly outperformed the traditional S&P 500, reaching a 12.4% gain compared to the benchmark's 12%. This shift followed a sharp selloff in AI-linked tech stocks, which make up about 45% of the S&...
Eli Lilly's board announced a dividend of $1.73 per share for the fourth quarter of 2026, payable on December 10 to shareholders recorded by November 13. This dividend reflects the company's ongoing commitment to returning value to shareholders amid ...
Thermo Fisher Scientific reported 5% organic growth, surpassing consensus by 2 percentage points, prompting management to raise its full-year growth forecast. Mettler-Toledo's local-currency sales grew 6%, exceeding its previous 3% guidance. TEVA als...
